The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products.
Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand.
The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.
The Federal Court of Australia has dismissed Spirit Pharmaceutical’s bid to introduce a generic version of painkiller OxyContin.
India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.
California-based biotechnology company Amgen has entered into a long-term partnership with Japanese pharmaceutical company Astellas Pharmas Inc to provide new medicines in Japan.
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Law firm Maurice Blackburn revealed on Monday that it will appeal against an Australian court decision that backed Myriad Genetics’ ownership of a human gene mutation linked to breast cancer.
In a report published by Thomson Reuters on February 20, the BRICK nations were shown to be filing almost as many patents as the G7 nations in 2011.
A judge at Australia’s Federal Court has upheld Myriad Genetics’ patent covering a human gene mutation linked to breast cancer, in the country’s first court ruling on whether isolated genes can be patented.